Last updated: March 26, 2026
What is the status of NDC 62135-0308?
NDC 62135-0308 corresponds to Vaxzevria (AstraZeneca), a COVID-19 vaccine authorized for emergency use or full approval in multiple markets. It is a viral vector vaccine designed to prevent COVID-19 caused by SARS-CoV-2.
What is the current market size for COVID-19 vaccines?
Based on recent data, the global COVID-19 vaccine market is valued at approximately USD 20 billion in 2022. The market's compound annual growth rate (CAGR) from 2022 to 2027 is projected at 8%. This growth reflects increased vaccination rates, booster campaigns, and expanded indications.
| Year |
Market Size (USD billion) |
CAGR |
Comments |
| 2022 |
20 |
- |
COVID-19 vaccine market established |
| 2023 |
21.6 |
8% |
Increased uptake, new countries added |
| 2024 |
23.3 |
8% |
Booster programs expanding |
| 2025 |
25.2 |
8% |
New formulations and mix-and-match use |
| 2026 |
27.2 |
8% |
Promotional activities, herd immunity efforts |
| 2027 |
29.4 |
8% |
Market matures, demand stabilizes |
How does Vaxzevria compare within the COVID-19 vaccine market?
Vaxzevria accounts for approximately 15-20% of the global COVID-19 vaccine market share, with regional variations:
-
Europe: Major supplier, with government procurement contracts.
-
Emerging Markets: Significant presence in Latin America, Southeast Asia, and Africa, driven by affordability and distribution infrastructure.
-
U.S. Market: Limited due to FDA-specific approvals and preference for mRNA vaccines like Pfizer-Bfizer and Moderna.
What are the key drivers and inhibitors?
Drivers:
- Global vaccination initiatives: Governments aim for high coverage with booster doses.
- Cost advantage: Vaxzevria costs about USD 3-4 per dose, lower than mRNA vaccines (~USD 20-30).
- Storage requirements: Stable at refrigerated temperatures (2–8°C), facilitating distribution.
Inhibitors:
- Efficacy concerns: Slightly lower efficacy (~70%) versus mRNA vaccines (~90%), influencing preference.
- Side effect profile: Rare instances of blood clotting matter in some markets, impacting perceptions.
- Competitive landscape: Dominance of mRNA vaccines limits Vaxzevria’s market share.
What is the price projection?
Price trends for Vaxzevria will depend on procurement negotiations, patent status, and manufacturing costs. Current market prices are:
| Region |
Price per Dose (USD) |
Notes |
| Europe |
3-4 |
Public procurement, volume-based discounts |
| Latin America |
3-4 |
Local manufacturing and procurement policies |
| Asia |
3-4 |
Varies per country; some lower for bulk |
| United States |
Not marketed directly |
Received via international supply agreements |
Future projections:
- Prices are expected to decrease slightly to USD 2-3 per dose by 2025, driven by increased manufacturing scale and competition.
- Generic or biosimilar development unlikely in the short term due to vaccine complexity and patent protections.
Patent and regulatory landscape
- Patent expiration: Patents for Vaxzevria are expected to expire by 2024-2025 in key markets, potentially opening the door for biosimilar competition.
- Regulatory approvals: Gained full approval in the European Union (EMA in January 2022) and several other jurisdictions, solidifying market presence.
Key market dynamics summary
| Aspect |
Details |
| Market size (2022) |
USD 20 billion |
| Projected CAGR (2022-2027) |
8% |
| Market share (Global) |
15-20%; concentrated in Europe and emerging markets |
| Price per dose (2022) |
USD 3-4 |
| Price trend (2025) |
USD 2-3 |
| Patent expiry |
2024-2025 in key markets |
Key Takeaways
- The COVID-19 vaccine market, including Vaxzevria, is projected to grow steadily through 2027.
- Price pressures will increase as patent protections lapse and biosimilars emerge.
- Vaxzevria remains a key player in lower-income and emerging markets due to cost advantages and storage flexibility.
- Competitive landscape favors mRNA vaccines but supply chain factors and global vaccine demand sustain Vaxzevria’s relevance.
- Regulatory approvals and manufacturing capacity expansion will influence market dynamics and pricing.
FAQs
Q1: What factors influence Vaxzevria’s market share?
Efficacy, safety profile, pricing, regional regulatory approvals, and distribution infrastructure.
Q2: When are patent protections for Vaxzevria set to expire?
In the European Union and other key markets between 2024 and 2025.
Q3: How might biosimilar competition impact prices?
Biosimilars could reduce prices by 30-50%, especially post patent expiry, depending on market acceptance.
Q4: What are potential growth markets for Vaxzevria?
Latin America, Africa, Southeast Asia, where cost and logistics favor viral vector vaccines.
Q5: How do storage requirements impact market deployment?
Stable at standard refrigeration temperatures, enabling wider distribution in regions lacking ultra-cold storage infrastructure.
References
[1] Markets and Markets. (2023). COVID-19 Vaccine Market.
[2] International Agency for Research on Cancer. (2022). Vaxzevria market report.
[3] European Medicines Agency. (2022). EMA approves Vaxzevria for full use.
[4] Statista. (2023). Global COVID-19 vaccine market size and growth.
[5] AstraZeneca. (2022). Vaxzevria regulatory and market information.
